{"schema_version":"secwatch.filing_event.v1","accession":"0001372514-26-000075","form_type":"8-K","ticker":"KPRX","cik":"0001372514","company_name":"KIORA PHARMACEUTICALS INC","filed_at":"2026-08-07T11:03:03+00:00","discovered_at":"2026-08-07T11:05:00.452806+00:00","generated_at":"2026-08-07T11:05:08.925811+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Kiora Q2 2026 net loss $2.1M; cash $16.8M; ABACUS-2 higher-dose enrollment underway","bullets":["Net loss $2.1M vs $2.2M YoY; R&D expense $2.1M net of $1.3M Théa reimbursement; G&A flat at $1.4M.","Cash and short-term investments $16.8M at June 30, up from $13.9M at March 31; runway into late 2028.","Private placement secured for up to $24M gross, $5M upfront, remainder contingent on milestone-based warrant exercise.","ABACUS-2 Phase 2 (KIO-301) enrolling higher 100 µg dose cohort; last patient first visit Q1 2027, topline Q3 2027.","KIO-104 KLARITY Phase 2 enrolling higher-dose cohort; initial clinical data expected late 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001372514-26-000075","json":"https://secwatch.observer/filing/0001372514-26-000075.json","markdown":"https://secwatch.observer/filing/0001372514-26-000075.md","text":"https://secwatch.observer/filing/0001372514-26-000075.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372514/000137251426000075/0001372514-26-000075-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372514/000137251426000075/kprx-20260807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-07T11:05:08.925811+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}